
Novo Nordisk A/S (NYSE:NVO) stock fell on Monday after the company released topline results from the 2-year primary analysis of evoke and evoke+ phase 3 trials in early-stage symptomatic Alzheimer’s disease.
The two trials were randomised, double-blinded, enrolled 3,808 adults, and evaluated the efficacy and safety of oral semaglutide compared to placebo on top of standard of care.